NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- Harvest Green Power ETF (159625) rises 1.22%, with a scale increase of 195 million yuan over the past week
- CSOP SK Hynix Daily (2x) Leveraged Product (07709.HK) Falls 4.22% in Afternoon Trade, Amplitude at 20.10%
- Csop Tesla Daily (2x) Leveraged Product(07766.HK) Rises 1.11% Intraday, Net Asset Value Per Unit at HK$97.885
- GF CNI New Energy Vehicle Battery ETF (159755) falls 2.56%, with the latest price at 0.91 yuan
- CSOP Coinbase Daily (2x) Leveraged Product(07711.HK) Surges 10.75% Intraday with Average Trading Price at HK$26.193
